Treatment with anti-TGF-β and anti-IL-4 mAbs weakens therapeutic potential of Salmonella-CFA/1 induced CD4+ T cellsa
| Treatmentb | CIA/Totalc | Day Onsetd | Maximum Scoree | Average Scoref | Cumulative Scoreg |
|---|---|---|---|---|---|
| PBS | 10/10 | 27.8 ± 1.6 | 10 | 7.2 ± 0.78 | 50.4 ± 7.11 |
| H696CD4+ T cells and IgG | 4/10 | 33 ± 5.35 | 4 | 1.44 ± 0.65 *† | 7.78 ± 4.65*† |
| H696CD4+ T cells and anti-IL-4 | 8/8 | 26.71 ± 2.29 | 8 | 3.62 ± 0.96 | 34.87 ± 11.09 |
| H696CD4+ T cells and anti-TGF-β | 8/8 | 27.25 ± 2.43 | 12 | 5.75 ± 0.86 | 49.37 ± 10.13 |
a Arthritis was induced in DBA/1 mice with 100 μg bovine CII in CFA on day 0.
b Salmonella-CFA/1 primed CD4+ T cells were adoptively transferred to mice with induced arthritis on day 15. i.p. mAb treatments were initiated on day of transfer, then weekly for a total of four doses (1 mg total of mAb/mouse).
c Number of mice with CIA/total in a group for 43 days after CII challenge.
d Mean day ± SEM of first symptoms onset in diseased mice only.
e Maximum score in group in entire observation period.
f Average clinical score per group on day 43 postinduction (end of observation period) calculated as sum of individual scores divided by the number of mice in group ± SEM. ∗, p < 0.005 as compared with PBS group; † p < 0.05 as compared with anti-IL-4 or anti-TGF-β mAb-treated group.
g Cumulative scores calculated as all scores during the period of observation divided by number of mice in each group. ∗p < 0.005 as compared with PBS- and anti-TGF-β-treated groups; † p < 0.05 as compared with anti-IL-4-treated group.